| Structural highlights
Function
GALT2_HUMAN Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Has a broad spectrum of substrates for peptides such as EA2, Muc5AC, Muc1a, Muc1b. Probably involved in O-linked glycosylation of the immunoglobulin A1 (IgA1) hinge region.[1] [2]
Publication Abstract from PubMed
Mucin-type O-glycosylation is the most abundant type of O-glycosylation. It is initiated by the members of polypeptide N-acetyl-alpha-galactosaminyltransferase (ppGalNAc-T) family and closely associated with both physiological and pathological conditions such as coronary artery disease or Alzheimer' s disease. The lack of direct and selective inhibitors of ppGalNAc-Ts has largely impeded research progress in understanding the molecular events in mucin-type O-glycosylation. Here, we report that a small molecule, the plant flavonoid luteolin, selectively inhibits ppGalNAc-Ts in vitro and in cells. We found that luteolin inhibits ppGalNAc-T2 through a peptide/protein-competitive manner but not promiscuously, e.g. via aggregation-based activity. X-ray structural analysis revealed that luteolin binds to the PxP motif-binding site found in most protein substrates, which was further validated by comparing the interactions between luteolin with wildtype enzyme and mutants using 1H NMR-based binding experiments. Functional studies disclosed that luteolin at least partially reduced production of beta-amyloid (Abeta) protein by selectively inhibiting the activity of ppGalNAc-T isoforms. In conclusion, our study provides key structural and functional details on luteolin inhibiting ppGalNAc-T activity, opening up the way for further optimization of more potent and specific ppGalNAc-T inhibitors. Moreover, our findings may inform future investigations into site-specific O-GalNAc glycosylation and into the molecular mechanism of luteolin-mediated ppGalNAc-T inhibition.
The small molecule luteolin inhibits N-acetyl-alpha-galactosaminyltransferases and reduces mucin-type O-glycosylation of amyloid precursor protein.,Liu F, Xu K, Xu Z, Rivas ML, Li X, Lu J, Delso I, Merino P, Hurtado-Guerrero R, Zhang Y J Biol Chem. 2017 Oct 23. pii: jbc.M117.814202. doi: 10.1074/jbc.M117.814202. PMID:29061849[3]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Wandall HH, Hassan H, Mirgorodskaya E, Kristensen AK, Roepstorff P, Bennett EP, Nielsen PA, Hollingsworth MA, Burchell J, Taylor-Papadimitriou J, Clausen H. Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. J Biol Chem. 1997 Sep 19;272(38):23503-14. PMID:9295285
- ↑ Iwasaki H, Zhang Y, Tachibana K, Gotoh M, Kikuchi N, Kwon YD, Togayachi A, Kudo T, Kubota T, Narimatsu H. Initiation of O-glycan synthesis in IgA1 hinge region is determined by a single enzyme, UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2. J Biol Chem. 2003 Feb 21;278(8):5613-21. Epub 2002 Nov 15. PMID:12438318 doi:http://dx.doi.org/10.1074/jbc.M211097200
- ↑ Liu F, Xu K, Xu Z, Rivas ML, Li X, Lu J, Delso I, Merino P, Hurtado-Guerrero R, Zhang Y. The small molecule luteolin inhibits N-acetyl-alpha-galactosaminyltransferases and reduces mucin-type O-glycosylation of amyloid precursor protein. J Biol Chem. 2017 Oct 23. pii: jbc.M117.814202. doi: 10.1074/jbc.M117.814202. PMID:29061849 doi:http://dx.doi.org/10.1074/jbc.M117.814202
|